TVTX Stock Recent News

Travere Therapeutics has successfully executed a significant restructuring to recover from previous setbacks and improve its financial health. It has built a compact pipeline of kidney therapy drugs with several having blockbuster potential. Its approved FILSPARI in treatment of IgAN is enjoying rapid growth.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 45,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a.

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Nivi Nehra - Corporate Participant e - Corporate Participant V - Corporate Participant i - Corporate Participant c - Corporate Participant P - Corporate Participant r - Corporate Participant e - Corporate Participant s - Corporate Participant i - Corporate Participant d - Corporate Participant Communications & Investor Relations - Corporate Participant e - Corporate Participant n - Corporate Participant t - Corporate Participant o - Corporate Participant f - Corporate Participant o - Corporate Participant r - Corporate Participant p - Corporate Participant o - Corporate Participant r - Corporate Participant a - Corporate Participant t - Corporate Participant e - Corporate Participant Peter Heerma - Chief Commercial Officer William E.

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.9 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update. “We continue to make strong progress against our strategic priorities, putting Travere on a trajectory for both near- and long-term growth. This quarter marked our strongest commercial performance to date, with increased momentum for FILSPARI resulting in significant growth in a dynamic IgAN market,” said Eric Dube, Ph.D., president and.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET Citi's 2025 Biopharma Back to School Conference Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET 2025 Wells Fargo Healthcare Conference Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET Cantor Global.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentation.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i.

NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.